Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

This study has been completed.
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: April 10, 2001
Last updated: February 25, 2009
Last verified: November 2005

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy. Sometimes the transplanted cells are rejected by the body's tissues. Peripheral stem cell transplantation with the person's own stem cells followed by donor peripheral stem cell transplantation may prevent this from happening.

PURPOSE: Phase II trial to study the effectiveness of combining chemotherapy with autologous peripheral stem cell transplantation and donor peripheral stem cell transplantation in treating patients who have multiple myeloma.

Condition Intervention Phase
Multiple Myeloma and Plasma Cell Neoplasm
Biological: sargramostim
Drug: cyclophosphamide
Drug: cyclosporine
Drug: fludarabine phosphate
Drug: melphalan
Procedure: peripheral blood stem cell transplantation
Phase 2

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Trial Of Autologous Stem Cell Transplant Followed By Mini-Allogeneic Stem Cell Transplant In Lieu Of Standard Allogeneic Bone Marrow Transplantation For Treatment Of Multiple Myeloma

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Study Start Date: April 2001
Primary Completion Date: February 2007 (Final data collection date for primary outcome measure)
Detailed Description:


  • Determine the incidence of early mortality in patients with multiple myeloma treated with melphalan and autologous peripheral blood stem cell (PBSC) transplantation followed by fludarabine, cyclophosphamide, and allogeneic PBSC transplantation.
  • Determine the incidence of early allogeneic graft failure (before day 100 after allogeneic PBSC transplantation) and the incidence of severe acute graft-versus-host disease (GVHD) in patients treated with this regimen.
  • Determine the toxicity of this regimen in these patients.
  • Determine the overall and disease-free survival of patients treated with this regimen.
  • Correlate changes in the T-cell population with clinical outcome, such as survival, in patients treated with this regimen.
  • Correlate changes in the T-cell population with the incidence of GVHD, use of immunosuppressive agents, and effects of fludarabine in patients treated with this regimen.
  • Determine the degree of chimerism after allogeneic PBSC transplantation and the time course over which it is established in patients treated with this regimen.

OUTLINE: This is a multicenter study.

Patients receive melphalan IV over 15 minutes on day -1. Autologous peripheral blood stem cells (PBSCs) are reinfused on day 0. Patients also receive sargramostim (GM-CSF) subcutaneously (SC) or IV over at least 30 minutes daily beginning on day 1 and continuing until blood counts recover. Beginning 100-182 days after autologous PBSC transplantation, patients receive fludarabine IV over 30 minutes on days -6 to -2 and cyclophosphamide IV over 1-2 hours on days -3 and -2. Allogeneic PBSCs are infused on day 0. Patients may receive a second allogeneic PBSC infusion on day 1. Patients also receive GM-CSF SC or IV over at least 30 minutes daily beginning on day 1 and continuing until blood counts recover. Cyclosporine is administered IV or orally twice daily as graft-versus-host disease (GVHD) prophylaxis, beginning on day -1 and continuing until day 60, followed by a taper in the absence of GVHD.

Patients are followed for 5 years.

PROJECTED ACCRUAL: A total 19-46 patients will be accrued for this study within 3 years.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Diagnosis of multiple myeloma meeting 1 of the following criteria:

    • Bone marrow plasmacytosis with at least 10% plasma cells
    • Sheets of plasma cells
    • Biopsy-proven plasmacytoma
  • Meets at least 1 of the following criteria:

    • Presence of myeloma (M)-protein in the serum
    • Presence of M-protein in the urine
    • Radiographic evidence of osteolytic lesions

      • Generalized osteoporosis allowed if at least 20% plasma cells in bone marrow
  • No non-secretory myeloma

    • Prior M-protein in serum or urine allowed provided patient is now in complete remission
  • Must be receiving conventional-dose chemotherapy as initial therapy or as salvage therapy
  • Must have HLA-A, -B, and -DR genotypically identical sibling donor



  • 18 to 70

Performance status:

  • ECOG 0-2

Life expectancy:

  • Not specified


  • See Disease Characteristics


  • AST no greater than 3 times upper limit of normal
  • Bilirubin less than 2.0 mg/dL


  • Not specified


  • LVEF greater than 40% at rest if symptomatic cardiac disease is present


  • DLCO greater than 50% of predicted (corrected for hemoglobin) if symptomatic pulmonary disease is present


  • Not pregnant or nursing
  • Fertile patients must use effective contraception


Biologic therapy:

  • No prior autologous or allogeneic peripheral blood stem cell or bone marrow transplantation


  • See Disease Characteristics
  • More than 28 days since prior chemotherapy (including primary chemotherapy for hematopoietic stem cell collection)
  • No other concurrent cytotoxic chemotherapy between autologous and allogeneic transplantation

Endocrine therapy:

  • Prior dexamethasone or other corticosteroids allowed
  • Concurrent corticosteroids between autologous and allogeneic transplantation allowed


  • Concurrent radiotherapy between autologous and allogeneic transplantation allowed


  • Not specified
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00014508

United States, Florida
Baptist Cancer Institute - Jacksonville
Jacksonville, Florida, United States, 32207-8554
Mayo Clinic - Jacksonville
Jacksonville, Florida, United States, 32224
United States, Massachusetts
Cancer Center at Tufts - New England Medical Center
Boston, Massachusetts, United States, 02111
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
United States, Minnesota
Mayo Clinic Cancer Center
Rochester, Minnesota, United States, 55905
United States, New Jersey
CCOP - Northern New Jersey
Hackensack, New Jersey, United States, 07601
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
New Brunswick, New Jersey, United States, 08903
United States, New York
MBCCOP-Our Lady of Mercy Cancer Center
Bronx, New York, United States, 10466
United States, Ohio
Ireland Cancer Center at University Hospitals of Cleveland and Case Western Reserve University
Cleveland, Ohio, United States, 44106-5065
MetroHealth's Cancer Care Center at MetroHealth Medical Center
Cleveland, Ohio, United States, 44109
United States, Pennsylvania
Penn State Cancer Institute at Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States, 17033-0850
Abramson Cancer Center at the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
Study Chair: Neal Flomenberg, MD Sidney Kimmel Cancer Center at Thomas Jefferson University
  More Information

Publications: Identifier: NCT00014508     History of Changes
Other Study ID Numbers: CDR0000068551
Study First Received: April 10, 2001
Last Updated: February 25, 2009

Keywords provided by National Cancer Institute (NCI):
refractory multiple myeloma
stage I multiple myeloma
stage II multiple myeloma
stage III multiple myeloma

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Fludarabine phosphate
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists processed this record on May 25, 2017